[Maxaquin in the combined treatment of tuberculosis].
In the context of experimental and clinical pharmacology, the paper provides evidence for that use of Maxaquine, a fluoroquinolone agent, is effective in the combined therapy of tuberculosis. Indications for its clinical use, dosage, and administration rates have been defined. Treatment regimens for patients isolating drug-sensitive and drug-resistant Mycobacteria tuberculosis in the presence or absence of contaminant nonspecific respiratory infections are presented. The duration of combined therapy has been defined depending on the pattern of a process and comorbidity.
Sokolova
G B
GB
Mozhokina
G N
GN
Kunichan
A D
AD
Elistratova
N A
NA
Perel'man
M I
MI
D000818:Animals; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D046508:Culture Techniques; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000382:microbiology; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D015363:Quinolones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin